WhistlePig Whiskey Welcomes New CEO Charles Gibb
Charles brings a wide breadth of global expertise to WhistlePig, particularly through the introduction of spirits and cocktail mixers to new audiences across various geographies. He launched Fever-Tree's North American arm, driving the mixer brand to the top of the ginger beer and tonic water charts while expanding their business to tackle multiple drinking occasions. Previously at Belvedere Vodka, Gibb spearheaded their global expansion efforts – establishing their Project RED and James Bond partnerships, and elevating the brand's presence worldwide. His tenure at Bacardi, Diageo and Moët Hennessy further underscores a career defined by strategic brand-building, innovation, and international market development.
'As a Scot, I could not be more excited to be joining this exceptional American whiskey brand. I thrive in an innovative, dynamic and entrepreneurial environment,' said Gibb. 'I've been involved with start-ups, initiated new markets and transformed developed markets by breaking apart paradigms to accelerate growth. That's exactly what WhistlePig does with whiskey. We have the perfect mix to shake up the market. Or stir up, if you prefer.'
WhistlePig has never been limited by the way things are done. From transforming an abandoned Vermont dairy barn into a pioneering grain-to-glass distillery to crafting category-defining releases, the brand has taken American whiskey to a new level of quality and innovation. Over the past two years, WhistlePig broke new ground by expanding beyond its signature Ryes into aged Bourbon and super-aged Single Malt. Today, WhistlePig is the market leader in ultra-premium Rye and fastest-growing ultra-premium Bourbon in the US. Gibb joins the team at an inflection point: building on WhistlePig's market disruption, driving brand growth, and championing bold innovation to offer consumers the world's best whiskey.
'Post an extensive search process, where we had an opportunity to consider various exceptional candidates, we are excited to welcome Charles to the WhistlePig team as we tackle the next phases of growth,' said Wilco Faessen, Co-Founder and Chairman of WhistlePig Whiskey. 'We also want to express our gratitude to Marty Birkel for taking the reins as CEO on an interim basis to enable a thorough search, and the upcoming transition.'
To learn more about WhistlePig Whiskey, visit whistlepigwhiskey.com. You can also check out WhistlePig Whiskey on Facebook, X and Instagram.
About WhistlePig Whiskey
Located off the grid on a 500-acre Vermont farm, WhistlePig Whiskey is crafted by a new generation of whiskey makers driven to reinvent and unlock the flavor of whiskey, starting with Rye. Through rebellious pursuit of experimenting and breaking boundaries in the industry, WhistlePig has become the leading independent craft whiskey brand, awarded Best Rye Whiskey (SFWSC 2021). WhistlePig is committed to becoming the best whiskey both on and for the planet, starting with its solar-powered Farm and distillery, and local grain-to-glass operation. For more information, head to whistlepigwhiskey.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
25 minutes ago
- The Hill
GOP congressman suggests he'd ‘lose money and go broke' if advisers stop stock trades
Rep. Rob Bresnahan (R-Pa.) dismissed the idea of directing his financial advisers to halt any stock trades amid his difficulties in establishing a blind trust that meets his standards, suggesting he would 'lose money and go broke.' Bresnahan, who has come under heat for continuing stock trades carried out by his advisers despite writing in support of banning congressional stock trades while campaigning for his seat, made the comment in an interview with local public news organization WVIA that was published Thursday. While Bresnahan said he has not been involved with the stock trades directed by his financial advisers, the outlet noted that he could order his advisers to stop trading stocks. 'And then do what with it?' Bresnahan told WVIA. 'Just leave it all in the accounts and just leave it there and lose money and go broke?' Bresnahan, a businessman whose net worth is estimated to be in the multi-millions, has said he would like to form a blind trust that would block him from having any control or knowledge of trades made on his behalf. But Bresnahan said he wants to use his existing financial advisers and wants to instruct the trustee to avoid investments that benefit foreign adversaries and avoid shorting American companies — running into problems with the House Ethics Committee. 'So, you would have to then find someone else that would even consider taking you to manage through a trustee account,' Bresnahan told WVIA. 'So, it became a disaster.' Last week, Bresnahan's lawyer sent a letter to the House Ethics committee saying that the Pennsylvania congressman prohibited his advisers from those types of investments or trades, the Washington Examiner reported. The letter also said Bresnahan is not consulted about any trade and is informed of trades only after they are complete. Bresnahan has also introduced a bill to ban stock trading for members of Congress and their spouses, and is open to working with other members on the issue. Still, Bresnahan has caught heat for being an active trader in Congress. The New York Times in April brought attention to Bresnahan continuing to trade despite writing a letter to the editor in The Citizens' Voice local newspaper in 2024 calling to ban congressional stock trading. The contrast between Bresnahan's statement during the campaign and his continued stock trades has made the freshman swing-district congressman a top target of Democrats hoping to win back the seat in 2026. 'Multi-millionaire Rob Bresnahan is full of shit,' Democratic Congressional Campaign Committee Spokesperson Eli Cousin said in a statement in response to the WVIA interview. 'He campaigned on a promise to ban congressional stock trading, but is now saying that he must continue his prolific trading in order to prevent himself from going broke. He doesn't care about his constituents – he only cares about his bottom line.' Bresnahan's spokesperson Hannah Pope fired back by pointing to trades reported in former Speaker Nancy Pelosi's (D-Calif.) financial disclosures. 'Rep. Bresnahan was a small business owner before becoming a Member of Congress, and unlike the DCCC's long-time benefactor, prolific stock trader Nancy Pelosi, he does not plan on being a Member of Congress for the rest of his career. He does not trade his own stocks and is unaware of what is traded or when,' Pope said in a statement. The trades reported by Pelosi that have garnered scrutiny were made by her husband Paul Pelosi, according to the disclosures, and Pelosi has thrown her support behind an effort to ban stock trading by members of Congress. Bresnahan's spokesperson continued: 'He believes Members of Congress should not be allowed to profit off the information they are entrusted with, which is why he introduced legislation to ban Congressional stock trading, restoring the integrity Americans expect and deserve from their government. As a Member of Congress, his number one focus will always be the people of Pennsylvania's Eighth Congressional District.' Bresnahan's comments come as legislative action on stock trading bans heat up. A Senate committee this week advanced a bill to ban congressional stock trading, and Rep. Anna Paulina Luna (R-Fla.) has pledged to file a discharge petition to try to force a vote on a bill to ban stock trading in the House.
Business Wire
25 minutes ago
- Business Wire
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo ® (ranibizumab injection) for the treatment of people with wet AMD. Results show that Susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California. 'These long-term results reinforce Susvimo's ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60,' said Levi Garraway, M.D., Ph.D., Genentech's chief medical officer and head of Global Product Development. 'These robust data reinforce our confidence in Susvimo's unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner.' 'People with wet AMD often experience suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections,' said study investigator John Kitchens, M.D., Retina Associates of Kentucky, who presented the data at ASRS. 'Continuous delivery of treatment with Susvimo may preserve vision in patients with wet AMD for longer in real-world clinical use than IVT injections.' In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132). Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care. In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at 5 years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.0 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 10.3 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort. The cohort of people who entered the Portal study from Archway is the largest cohort of people with wet AMD to be followed prospectively and continuously for five years in a clinical study. Susvimo provides continuous delivery of a customized formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss. About the Archway study and its open-label extension study (Portal) Archway (NCT03677934) was a randomized, multicenter, open-label Phase III study evaluating the efficacy and safety of Susvimo refilled every six months at fixed intervals, compared to monthly IVT ranibizumab 0.5 mg in 415 people living with wet AMD. Patients were randomized 3:2 to Susvimo (n = 248) or intravitreal (IVT) ranibizumab injections (n = 167). Patients enrolled in Archway were responders to prior treatment with anti-VEGF therapy. In both study arms, patients were treated with at least three anti-VEGF injections within the six months prior to their Archway screening visit, with an average of five anti-VEGF injections before randomization. The primary endpoint of the study was the change in BCVA score from baseline at the average of Week 36 and Week 40. Secondary endpoints include safety, overall change in vision (BCVA) from baseline and change from baseline in center point thickness over time. Patients who completed the study at week 96 were eligible to enter the Portal open-label extension study. In Portal, people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort), while those originally treated with monthly IVT ranibizumab injections in Archway received the Susvimo implant and then refills every six months (IVT-Susvimo cohort). Portal is ongoing. About Wet Age-Related Macular Degeneration (AMD) Age-related macular degeneration (AMD) is a condition that affects the macula, the part of the eye that provides sharp, central vision needed for activities like reading. It is a leading cause of blindness for people aged 60 and over in the U.S. Wet, or neovascular, AMD is an advanced form of the disease that can cause rapid and severe vision loss. Approximately 20 million people in the U.S. have some form of AMD, and of those, about 1.5 million have late-stage AMD, which includes wet AMD. Wet AMD is caused by growth of abnormal blood vessels, also referred to as choroidal neovascularization (CNV), into the macula. These vessels leak fluid and blood and cause scar tissue that destroys the central retina. This process results in a deterioration of sight over a period of months to years. Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Susvimo to help minimize barriers to access and reimbursement. Patients can call 833-EYE-GENE for more information. For people who qualify, Genentech offers patient assistance programs through Genentech Access Solutions. More information is also available at (866) 4ACCESS/(866) 422-2377 or Visit for additional information. Susvimo ® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo continuously delivers a customized formulation of ranibizumab over time. Susvimo is indicated for intravitreal use via the Susvimo eye implant only. Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels. Susvimo was previously called the Port Delivery System with ranibizumab in the U.S. The customized formulation of ranibizumab delivered by Susvimo is different from the ranibizumab intravitreal injection, a medicine marketed as Lucentis ® (ranibizumab injection), which is approved to treat wet, or neovascular, age-related macular degeneration (AMD) and other retinal diseases. Lucentis was first approved for wet AMD by the FDA in 2006. Susvimo Indication Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor inhibitor medication. Susvimo Important Safety Information WARNING: ENDOPHTHALMITIS The Susvimo implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Warnings and Precautions: The Susvimo implant and the procedures associated with inserting, filling, refilling, and (if medically necessary) removing the implant can cause other serious side effects, including: An eye infection (endophthalmitis). Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye, including blindness. Endophthalmitis requires urgent (same-day) medical or surgical treatment. A missing layer on top of the white part of the eye (conjunctival erosion). Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye, which may result in exposure of the implant. Conjunctival erosion may require surgical treatment. An opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye, which may cause the implant to be exposed. Conjunctival retraction may require surgical treatment. Tear and separation of layers of the retina (rhegmatogenous retinal detachment). Rhegmatogenous retinal detachment is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Rhegmatogenous retinal detachment requires surgical treatment. Implant movement (implant dislocation): This movement may require surgical treatment to correct. Implant damage: Damage to the implant that prevents continued treatment (refills) with Susvimo. If the implant is not able to be properly refilled, a patient's wet AMD may be inadequately treated and a physician may remove the implant and/or change the treatment. Bleeding (vitreous hemorrhage): Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. This may require an additional eye surgery. Bump on top of the white layer of the eye (conjunctival bleb): Conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. This may require medical or surgical treatment. Temporary decrease in vision after the Susvimo procedure. Who should not receive Susvimo? Patients who have an infection in or around their eye, have active inflammation in their eye, or have had an allergic reaction to ranibizumab or any of its ingredients in Susvimo in the past. Information for patients who are of childbearing potential If patients are pregnant, think that they might be pregnant, or plan to become pregnant. It is not known if Susvimo will harm an unborn baby. Patients should use birth control (contraception) during treatment with Susvimo and for 12 months after the last refill of Susvimo. If patients are breastfeeding or plan to breastfeed. Susvimo is not recommended during breastfeeding. It is not known if Susvimo passes into breast milk. Adverse Reactions The most common adverse reactions were blood on the white of the eye, redness in the white of the eye, sensitivity to light, and eye pain. These are not all the possible side effects of Susvimo. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. Please see additional Important Safety Information in the full Susvimo Prescribing Information, including BOXED WARNING or visit About Lucentis ® (ranibizumab injection) Lucentis ® is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV). Lucentis was developed by Genentech, a member of the Roche Group. The company retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. Outside the United States, Lucentis is approved in more than 120 countries to treat adult patients with wet AMD, and for the treatment of visual impairment due to DME, due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and due to choroidal neovascularization (CNV). Lucentis Important Safety Information Lucentis is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in Lucentis. Hypersensitivity reactions may manifest as severe intraocular inflammation. Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Increases in intraocular pressure have been noted both pre-injection and post-injection with Lucentis. Although there was a low rate of arterial thromboembolic events (ATEs) observed in the Lucentis clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with Lucentis compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded. Retinal vasculitis and/or retinal vascular occlusion have been reported. Patients should be instructed to report any change in vision without delay. In the Lucentis Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see Lucentis full Prescribing Information, available here: About Genentech in Ophthalmology Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases, including rare and inherited conditions. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit
Business Wire
25 minutes ago
- Business Wire
Udemy to Present at the Canaccord Genuity 45th Annual Growth Conference
SAN FRANCISCO--(BUSINESS WIRE)-- Udemy (Nasdaq: UDMY), a leading AI-powered skills acceleration platform, today announced that Chief Executive Officer Hugo Sarrazin will participate in a fireside chat session during the Canaccord Genuity 45th Annual Growth Conference. On Tuesday, August 12, 2025 at 9:00 a.m. ET, a live webcast of the fireside chat discussion will be available through the ' Events & Presentations ' section of Udemy's investor relations website at An archived replay of the webcast will be available for approximately 90 days following the event. About Udemy Udemy (Nasdaq: UDMY) is an AI-powered skills acceleration platform transforming how companies and individuals across the world build the capabilities needed to thrive in a rapidly evolving workplace. By combining on-demand, multi-language content with real-time innovation, Udemy delivers personalized experiences that empower organizations to scale workforce development and help individuals build the technical, business, and soft skills most relevant to their careers. Today, thousands of companies, including Ericsson, Samsung SDS America, On24, Tata Consultancy Services, The World Bank, and Volkswagen, rely on Udemy Business for its enterprise solutions to build agile, future-ready teams. Udemy is headquartered in San Francisco, with hubs across the United States, Australia, India, Ireland, Mexico and Türkiye.
